{"prompt": "['2017N323364_01', 'CONFIDENTIAL', '2019N398531_00', '207626', 'GSK conducted a Phase III study comparing once-daily FF/UMEC/VI to twice-daily', 'budesonide/formoterol (400/12 mcg) in COPD participants that were symptomatic and at', 'risk of an exacerbation despite receiving maintenance therapy (CTT116853).', 'FF/UMEC/VI demonstrated statistically significant improvements in trough FEV1, a', 'statistically significant reduction in the annual rate of moderate or severe COPD', 'exacerbations, and a statistically significant reduction of COPD symptoms (using', 'Exacerbations and Chronic Pulmonary Disease - Respiratory Symptoms [EXACT-RS])', 'when compared to budesonide/formoterol. Additionally, clinically meaningful', \"improvements from baseline in St. George's Respiratory Questionnaire (SGRQ) total\", 'score were observed, with a statistically significant improvement compared to', 'budesonide/formoterol. This Phase III study provided compelling efficacy data compared', 'with an established ICS/LABA and demonstrated the clinical value of single inhaler', 'triple-therapy compared to ICS/LABA therapy in patients with COPD.', 'As fixed dose combinations of LAMA/LABA therapy remain relatively new, and ICS', 'monotherapy is not indicated for the treatment of COPD, the two most frequent treatment', 'pathways that lead to \"open\\' triple therapy are the escalation of therapy from either an', 'ICS/LABA fixed dose combination or from LAMA monotherapy. A prior study', 'demonstrated that participants with COPD may remain symptomatic despite the use of', 'LAMA or LABA monotherapy. Participants that remained symptomatic despite treatment', \"with LAMA monotherapy, stepped up to 'open' triple therapy by the addition of\", 'ICS/LABA therapy, which resulted in greater improvements in lung function and', 'HRQoL, compared LAMA monotherapy.', 'The primary purpose of this study is to evaluate lung function and HRQoL after 84 days', 'of treatment with a single inhaler triple therapy combination of FF/ UMEC/VI', '(100/62.5/25 mcg) once daily via the ELLIPTATN compared with tiotropium (18 mcg)', 'once daily, in a patient population appropriate for triple therapy.', 'Objectives and Endpoints:', 'Objectives', 'Enppoints', 'Primary', 'Primary', 'Change from baseline in trough FEV1 at', 'To evaluate the effect of single inhaler', 'Week 12 (Day 85)', 'triple therapy (FF/UMEC/VI) compared', 'to tiotropium after 12 weeks of', 'Secondary', 'treatment on lung function', 'Change from baseline in trough FEV1', 'on Day 28 and Day 84', '11']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Objectives', 'Endpoints', 'Other', 'Proportion of responders based on the St', 'To evaluate the effect of single inhaler', \"George's Respiratory Questionnaire\", 'triple therapy (FF/UMEC/VI) compared', '(SGRQ) Total Score at Week 4 and', 'to tiotropium after 12 weeks of', 'Week 12', 'treatment on Health Status', 'Change from baseline in SGRQ Total', 'Score at Week 4 and Week 12', 'Proportion of responders based on the', 'To evaluate the effect of single inhaler', 'COPD Assessment Test (CAT) Total', 'triple therapy (FF/UMEC/VI) compared', 'Score at Week 4 and Week 12', 'to tiotropium after 12 weeks of', 'treatment on Health Status', 'Change from baseline in CAT Total', 'Score at Week 4 and Week 12', 'To evaluate the effect of single inhaler', 'triple therapy (FF/UMEC/VI) compared', 'to tiotropium after 12 weeks of', 'Moderate or severe exacerbation event', 'treatment on COPD exacerbations', 'Safety', 'To evaluate the safety profile of single', 'Incidence of adverse events', 'inhaler triple therapy (FF/UMEC/VI)', 'compared to tiotropium over 12 weeks', 'Vital signs', 'of treatment', 'Overall Design:', 'This is a Phase IV, 12-week, randomised, double-blind, double-dummy, parallel group,', 'multicentre study evaluating once-daily single inhaler triple therapy (FF/UMEC/VI)', 'delivered via the ELLIPTA, compared to once daily tiotropium, in participants with', 'COPD.', '12']\n\n###\n\n", "completion": "END"}